News

FDA approves Zepbound, a new medication for chronic obesity

The FDA has approved Zepound, a drug made by Eli Lily to treat chronic obesity. The medication contains the active ingredient tirzepatide, which was approved in 2022 to treat type 2 diabetes. Tirzepatide is a similar medication to semaglutide that was also developed for diabetes treatment under the name Ozempic and is now being sold as Wegovy. 

Studies on both have shown high effectiveness in treating diabetes and obesity.

How is Zepbound different from Wegovy?

Both are weekly injection medications initially approved for treating type 2 diabetes, with notable weight loss effects observed in clinical trials. While Wegovy is already available in the market, Zepbound has recently received FDA approval and is anticipated to be available later this year.

Belonging to the class of drugs known as GLP-1 agonists, both medications imitate the digestive hormone glucagon-like peptide 1 (GLP-1), released by the intestines during meals. GLP-1 stimulates insulin production, lowers blood glucose levels, and induces feelings of fullness while suppressing appetite. 

Tirzepatide, in addition to mimicking GLP-1, also imitates another gut hormone called gastric inhibitory polypeptide (GIP), believed by scientists to have a similar effect as GLP-1.

Regarding weight reduction, both drugs demonstrate significant efficacy. A March 2021 study on semaglutide, published in The New England Journal of Medicine, revealed an average weight loss of 14.9% over a year compared to 2.4% in the placebo group. Another study in September 2022, published in JAMA Network Open, reported a mean weight loss of approximately 27 pounds (12.3 kilograms) after six months.

Tirzepatide exhibits impressive effectiveness as well. A pivotal July 2022 study in The New England Journal of Medicine disclosed that individuals taking a lower dose achieved an average weight reduction of 16%, equivalent to 35.5 pounds (16 kilograms) in about a year. 

Those on a higher dose experienced a 21.4% reduction, equivalent to 49 pounds (22 kilograms). These outcomes surpassed the placebo group, which showed an average reduction of 2.4% or 5.3 pounds (2.4 kilograms).

Liz Daunton

Recent Posts

US Bombers Pulled From UK Base Amid Iran Threat

The United States has removed its bombers from a British military base that has played…

5 days ago

North Korea Missile Launch Raises Regional Security Concerns

North Korea fired two short-range ballistic missiles toward the East Sea on September 20, according…

2 weeks ago

US Measles Outbreak Grows as Deaths Raise Concern

The United States is experiencing its most serious measles surge in decades, with thousands of…

2 weeks ago

Rising Fuel Costs and Shipping Delays Threaten US Businesses

US businesses are once again dealing with serious disruptions across the supply chain, but the…

3 weeks ago

Trump and Vance Push Back on AI Safety Concerns

  The debate over AI safety concerns is becoming increasingly prominent in Washington as President…

3 weeks ago

9/11 Cancer Cases Rise Among Survivors 25 Years Later

Twenty-five years after the September 11 attacks, the health consequences for people exposed to the…

4 weeks ago